Biogen Dividend Yield vs Net Income Analysis
BIIB Stock | USD 194.38 3.86 2.03% |
Biogen financial indicator trend analysis is way more than just evaluating Biogen Inc prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Biogen Inc is a good investment. Please check the relationship between Biogen Dividend Yield and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product.
Dividend Yield vs Net Income
Dividend Yield vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Biogen Inc Dividend Yield account and Net Income. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Biogen's Dividend Yield and Net Income is -0.48. Overlapping area represents the amount of variation of Dividend Yield that can explain the historical movement of Net Income in the same time period over historical financial statements of Biogen Inc, assuming nothing else is changed. The correlation between historical values of Biogen's Dividend Yield and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Dividend Yield of Biogen Inc are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Dividend Yield i.e., Biogen's Dividend Yield and Net Income go up and down completely randomly.
Correlation Coefficient | -0.48 |
Relationship Direction | Negative |
Relationship Strength | Very Weak |
Dividend Yield
Dividend Yield is Biogen Inc dividend as a percentage of Biogen stock price. Biogen Inc dividend yield is a measure of Biogen stock productivity, which can be interpreted as interest rate earned on an Biogen investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in Biogen Inc financial statement analysis. It represents the amount of money remaining after all of Biogen Inc operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from Biogen's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Biogen Inc current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. At present, Biogen's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 17.67, whereas Tax Provision is forecasted to decline to about 128.5 M.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 8.9B | 7.9B | 7.3B | 3.9B | Total Revenue | 11.0B | 10.2B | 9.8B | 10.3B |
Biogen fundamental ratios Correlations
Click cells to compare fundamentals
Biogen Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biogen fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 27.2B | 24.6B | 23.9B | 24.6B | 26.8B | 28.2B | |
Short Long Term Debt Total | 6.4B | 7.8B | 7.6B | 6.6B | 7.3B | 7.7B | |
Other Current Liab | 3.4B | 3.3B | 3.3B | 2.8B | 838.4M | 969.8M | |
Total Current Liabilities | 4.9B | 3.7B | 4.3B | 3.3B | 3.4B | 3.6B | |
Total Stockholder Equity | 13.3B | 10.7B | 11.0B | 13.4B | 14.8B | 15.5B | |
Property Plant And Equipment Net | 3.7B | 3.8B | 3.8B | 3.7B | 3.7B | 3.9B | |
Net Debt | 3.5B | 6.5B | 5.3B | 3.2B | 6.3B | 6.6B | |
Retained Earnings | 16.5B | 14.0B | 13.9B | 16.5B | 17.6B | 18.5B | |
Cash | 2.9B | 1.3B | 2.3B | 3.4B | 1.0B | 723.1M | |
Non Current Assets Total | 18.9B | 17.7B | 16.0B | 14.8B | 20.0B | 21.0B | |
Non Currrent Assets Other | (3.2B) | (1.4B) | 1.9B | 1.5B | 284.3M | 270.1M | |
Cash And Short Term Investments | 4.5B | 2.6B | 3.8B | 4.9B | 1.0B | 1.5B | |
Net Receivables | 1.9B | 1.9B | 1.5B | 2.1B | 2.1B | 2.2B | |
Common Stock Shares Outstanding | 187.4M | 161.3M | 149.6M | 146M | 145.6M | 283.0M | |
Liabilities And Stockholders Equity | 27.2B | 24.6B | 23.9B | 24.6B | 26.8B | 28.2B | |
Non Current Liabilities Total | 9.0B | 10.2B | 8.6B | 7.9B | 8.6B | 9.0B | |
Other Current Assets | 1.2B | 1.3B | 1.2B | 1.4B | 1.2B | 1.2B | |
Other Stockholder Equity | (3.0B) | (3.0B) | (2.8B) | (2.9B) | (2.7B) | (2.5B) | |
Total Liab | 13.9B | 13.9B | 12.9B | 11.2B | 12.0B | 12.6B | |
Property Plant And Equipment Gross | 3.7B | 3.8B | 3.8B | 3.7B | 6.1B | 6.4B | |
Total Current Assets | 8.4B | 6.9B | 7.9B | 9.8B | 6.9B | 7.2B | |
Accumulated Other Comprehensive Income | (135.2M) | (299M) | (106.7M) | (164.9M) | (153.7M) | (146.0M) | |
Intangible Assets | 3.5B | 3.1B | 2.2B | 1.9B | 8.4B | 8.8B | |
Accounts Payable | 530.8M | 454.9M | 589.2M | 491.5M | 403.3M | 423.5M | |
Short Term Investments | 2.3B | 1.6B | 1.3B | 1.5B | 1.5B | 0.0 | |
Inventory | 804.2M | 1.1B | 1.4B | 1.3B | 2.5B | 2.7B | |
Other Liab | 4.2B | 2.4B | 2.0B | 1.3B | 1.5B | 969.6M | |
Other Assets | 3.2B | 4.2B | 3.4B | 1.7B | 1.9B | 2.0B | |
Long Term Debt | 4.5B | 7.4B | 6.3B | 6.3B | 6.8B | 7.1B | |
Property Plant Equipment | 3.2B | 3.4B | 3.4B | 3.3B | 3.8B | 2.1B | |
Good Will | 5.8B | 5.8B | 5.8B | 5.7B | 6.2B | 3.2B | |
Net Tangible Assets | 4.1B | 1.9B | 2.9B | 5.8B | 6.7B | 4.1B | |
Noncontrolling Interest In Consolidated Entity | (4.1M) | (14.2M) | 63.5M | (9.5M) | (8.6M) | (8.1M) | |
Retained Earnings Total Equity | 16.5B | 14.0B | 13.9B | 16.5B | 18.9B | 11.5B |
Pair Trading with Biogen
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biogen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biogen will appreciate offsetting losses from the drop in the long position's value.Moving together with Biogen Stock
0.68 | JNJ | Johnson Johnson Financial Report 18th of July 2024 | PairCorr |
Moving against Biogen Stock
0.75 | NUVB | Nuvation Bio Financial Report 2nd of May 2024 | PairCorr |
0.62 | IOVA | Iovance Biotherapeutics Financial Report 14th of May 2024 | PairCorr |
0.58 | JSPRW | Jasper Therapeutics | PairCorr |
0.48 | ZNTL | Zentalis PharmaceuticalsL Buyout Trend | PairCorr |
0.47 | IMMP | Immutep Ltd ADR | PairCorr |
The ability to find closely correlated positions to Biogen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biogen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biogen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biogen Inc to buy it.
The correlation of Biogen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biogen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biogen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biogen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biogen Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Complementary Tools for Biogen Stock analysis
When running Biogen's price analysis, check to measure Biogen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biogen is operating at the current time. Most of Biogen's value examination focuses on studying past and present price action to predict the probability of Biogen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biogen's price. Additionally, you may evaluate how the addition of Biogen to your portfolios can decrease your overall portfolio volatility.
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Transaction History View history of all your transactions and understand their impact on performance | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |
Is Biogen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biogen. If investors know Biogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biogen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.55) | Earnings Share 7.97 | Revenue Per Share 67.972 | Quarterly Revenue Growth (0.06) | Return On Assets 0.0458 |
The market value of Biogen Inc is measured differently than its book value, which is the value of Biogen that is recorded on the company's balance sheet. Investors also form their own opinion of Biogen's value that differs from its market value or its book value, called intrinsic value, which is Biogen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biogen's market value can be influenced by many factors that don't directly affect Biogen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biogen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biogen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biogen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.